Efficacy and safety of 1-week Helicobacter pylori eradication therapy and 7-week rebamipide treatment after endoscopic submucosal dissection of early gastric cancer in comparison with 8-week PPI standard treatment: a randomized, controlled, prospective, multicenter study Abstract Background Endoscopic submucosal dissection (ESD) has been developed for early gastric cancer (EGC). Helicobacter pylori eradication therapy has been reported to have a preventive effect against metachronous recurrence of EGC after ESD. However, the efficacy and safety of eradication therapy on ESD-induced ulcer healing are not clear. In a randomized control study, we compared the standard therapy (8-week proton pump inhibitor) and eradication therapy combined with subsequent treatment with 7-week rebamipide for healing ESD-induced ulcers. Methods A multicenter, randomized, open-label study was conducted. In group A, patients received 20 mg of omeprazole for 56 days. In group B, patients received 40 mg of omeprazole, 1,500 mg of amoxicillin, and 800 mg of clarithromycin for 7 days, and then 300 mg of rebamipide for 49 days. The primary end point was to evaluate the scarring ratio. Results The scarring rate in group A was significantly higher than that in group B [85.0 % (34/40) vs. 56.8 % (21/ 37), P = 0.011]. The scarring rate of ulcers with an area C565.5 mm 2 in group A was significantly higher than that in group B [78.9 % (15/19) vs. 37.5 % (6/16), P = 0.018]. There was no significant difference between the groups in the scarring rate of smaller ulcers. No serious adverse events were observed in any of the patients in either group. 
Introduction
Endoscopic mucosal resection (EMR) has been established as a minimally invasive treatment for early stage gastric cancer (EGC) [1, 2] . However, en-bloc resection in patients with large tumors is often not indicated by EMR. Recently, endoscopic submucosal dissection (ESD) has been developed for EGC, and this procedure enables larger lesions to be resected, thereby yielding improved rates of successful en-bloc resection [3] . Uemura et al. demonstrated that Helicobacter pylori (H. pylori) had an important role in gastric carcinogenesis, since almost all non-cardiac gastric cancers develop from a background of H. pylori-infected mucosa [4] . In addition, H. pylori eradication therapy was effective for the prevention of metachronous recurrence of gastric cancer after ESD [5] .
For artificial gastric ulcers after ESD, 8-week treatment with a proton pump inhibitor (PPI) or histamine 2 receptor antagonist was sufficient for healing [6, 7] . On the other hand, eradication monotherapy is an alternative treatment for healing EMR-induced gastric ulcers [8] . However, the efficacy and safety of eradication therapy for healing ESDinduced gastric ulcers are not clear. It is well known that H. pylori infection is one of the etiologies inducing gastric ulcers. In previous reports, the healing effect of H. pylori-eradication monotherapy on gastric ulcers in H. pylori-infected Japanese patients was not superior to 8-week PPI therapy [9] . Eradication monotherapy may be insufficient to heal ESD-induced gastric ulcers. Terano et al. investigated the efficacy of 7-week treatment with rebamipide, a gastro-protective anti-ulcer drug, in patients with gastric ulcers after H. pylori eradication therapy compared with placebo. Rebamipide promoted gastric ulcer healing regardless of the success or failure of H. pylori eradication [10] . Fujiwara et al. reported that combination therapy with PPI and rebamipide showed a superior healing effect compared with PPI in patients with ESD-induced gastric ulcers [11] .
In a randomized control study, we compared a group treated with PPI for 8 weeks after ESD (group A; standard therapy) and a group treated with 1 week of eradication therapy after ESD and subsequently treated with rebamipide for 7 weeks (group B) in EGC patients who were positive for H. pylori.
Methods

Study setting
This multicenter, randomized, open-label study was conducted in Japan. This study was conducted in accordance with the ethical principles of the Declaration of Helsinki. The protocol was approved by the ethics committees at each study site. All patients provided written informed consent. This study was registered with UMIN: registration no. UMIN000003181.
Patients
Patients included in this study underwent ESD based on whether their H. pylori-infected EGC fit the criteria proposed by guidelines of the Japanese Gastric Cancer Association [12] . Patients who received oral nonsteroidal antiinflammatory drugs, continuous corticosteroids, or an antithrombotic drug, who had a complicated peptic ulcer, a history of GI surgery, or received H. pylori eradication therapy were excluded.
Treatment
Patients were randomized to two study groups (group A and B). All patients received intravenous administration of 40 mg omeprazole on the first 2 days after ESD; then, the study drugs were administered. In group A, patients received 20 mg of omeprazole daily for 56 days. In group B, patients received 20 mg of omeprazole, 750 mg of amoxicillin, and 400 mg of clarithromycin twice daily for 7 days, and then 100 mg of rebamipide three times daily for 49 days. Endoscopic examination was performed at day 2, 7, and 58 after ESD, and the artificial ulcer area was calculated. In addition, ulcer stages such as healing and scar stages were evaluated. In group B, the 13 C-urea breath test (UBit Ò ; Otsuka, Tokyo, Japan) was performed on day 84 after ESD to confirm the presence or absence of H. pylori.
The presence of H. pylori infection was determined by histological evaluation (modified Giemsa staining), the rapid urease test (CLOtest Ò ; Kimberley-Clark, Draper, UT, USA), serum antibody test, or 13C-urea breath test. When one of these tests was positive, we would score the patient as positive for the presence of H. pylori infection. Eradication of H. pylori was defined as successful when the results of both the rapid urease test and histology were negative or when those of the 13C-urea breath test were negative, with the cutoff value of delta over baseline as 2.5 %.
Sizes of the artificial ulcer were measured using the upper GI endoscopic measure (M2-4, Olympus, Tokyo, Japan). The ulcer area was presumed to be the approximate value of the ellipse; it is calculated by measuring the diameter of the longitude and transverse of the artificial ulcer. A scar was defined as the disappearance of the white coat in the center of the ulcer area. Bleeding was defined as hematemesis or melena that required endoscopic hemostasis and decreased the hemoglobin count by more than 2 g/dl, occurring from the time of treatment to within 56 days after ESD.
Randomization
A randomization code was assigned a treatment code corresponding to each study drug code by the allocation manager from the contract research organization for the registration center (Kondo Photo Process Co., Ltd., Osaka, Japan). The study drug allocation manager sealed the assignment list and kept it sealed until the designated time for unmasking.
Evaluation
The primary end point was to evaluate the healing ratio to scar stage to the final evaluation time point comparison between group A and B. Secondary end points were to evaluate the change in the reduction ratio of the artificial ulcer from baseline to the final evaluation time point comparison between the groups. The effect of the H. pylori eradication therapy (stratified according to success or failure) and artificial ulcer area at baseline (stratified according to C median area or \ median area) was also evaluated. In addition, adverse events were also recorded. Baseline was defined as the measured value at day 2 after the ESD procedure, and the final evaluation time point was defined as the measured value at day 56. If the study drug treatment was not completed, the measured value at the time of dropout was defined as the final evaluation time point.
Statistical analysis
In a previous report, the healing ratio with rebamipide treatment at day 56 after H. pylori eradication therapy was 70 % [10] . On the other hand, administration of PPI at 56 days after ESD was 100 % [13] . Our hypothesis is that the difference in both groups is at least 10 %. Sample size was calculated based on this hypothesis. A two-sided test with a 0.05 significance level and 80 % power (a = 0.05, b = 0.20) would require 37 subjects per group.
The categorical data were analyzed by chi-square test, Fisher's exact test, or Mann-Whitney's U test. The continuous data were analyzed by paired t test.
Statistical significance was defined as P \ 0.05. All statistical analyses were performed using SAS Jump version 10.0.0 software (SAS Institute, Cary, NC).
Results
This study was conducted from April 2010 through March 2011 at nine study sites. Of 88 patients who received at least one dose of the study drug, 6 who deviated from the protocol and 2 at the physician's request were excluded from this study (Fig. 1) . Eighty patients were randomized in this study. One patient in group A was excluded from all analysis sets because of loss to follow-up, and two patients in group B were excluded because of loss to follow-up. Forty patients in group A and 37 patients in group B completed treatment with the study drugs and were evaluated in all analysis sets. Patient's demographic data and characteristics did not show statistically significant differences between the groups (Table 1) .
At the final evaluation time point, 34 of 40 (85.0 %) patients in group A and 21 of 37 (56.8 %) in group B (P = 0.0107) had progressed to the scar stage ( Table 2) .
The change in the reduction ratio of the artificial ulcer area at day 7 was 15.2 ± 52.5 % in group A and 38.1 ± 24.0 % in group B, respectively (P = 0.0195). The change in the reduction ratio of the artificial ulcer area at the final evaluation time point was 98.0 ± 4.8 % in group A and 92.3 ± 12.0 % in group B, respectively (P = 0.0096) (Fig 2) .
Change in progression to scar at the final evaluation time point by stratifying the ulcer size was evaluated. For those with a [565.5 mm 2 (median was 565.5 mm 2 ) artificial ulcer area at baseline, 15 of 19 (79.0 %) patients were evaluated as being at the scar stage in group A and 7 of 18 (59.5 %) in group B, respectively (P = 0.0131). In artificial ulcer areas of less than 565.5 mm 2 , there was no significant difference between the groups (Table 3) .
The change in progressing to scar at the final evaluation time point stratifying for the effect of H. pylori eradication therapy was also evaluated. In case of H. pylori eradication, 34 of 40 (85.0 %) patients were evaluated as being at scar stage in group A and 17 of 29 (58.6 %) in group B, respectively (P = 0.0138). In case of failure, there was no statistical significance (Table 4) .
Adverse events
Perforation was observed in one ESD patient in group A, and bleeding was observed in one patient at day 5 in group B. Diarrhea was observed in two patients in group B.
Discussion
In the present study, we showed two obvious results. First, serious adverse events such as bleeding from the artificial ulcer after ESD were not observed in patients with H. Comparisons between group A and B were performed using Fisher's exact test pylori eradication therapy compared with those with 8 weeks of PPI therapy as standard therapy for the artificial ulcer. No previous evidence had been reported about performing H. pylori eradication therapy after hemostatic treatment in active gastric ulcer patients with bleeding. In this study, performing H. pylori eradication therapy 3 days after ESD was safe without worsening the ulcers and without bleeding. Our result may suggest optimal timing of H. pylori eradication therapy as one of the options for patients who have undergone ESD. Second, we showed that H. pylori eradication therapy plus 7 weeks of rebamipide monotherapy was not superior to PPI monotherapy. Since artificial ulcers were reduced by approximately 90 % in both groups, a slightly longer term observation might be required for unhealed ulcers with small white coats at 8 weeks.
In artificial ulcer areas of less than 565.5 mm 2 , there was no significant difference between PPI monotherapy and H. pylori eradication therapy plus 7 weeks of rebamipide monotherapy. Therefore, rebamipide monotherapy following H. pylori eradication therapy was considered an optimal therapeutic option in patients with smaller sized artificial ulcers (\565.5 mm 2 ). In patients with artificial ulcer areas of more than 565.5 mm 2 , 7 weeks of PPI therapy in place of rebamipide might be considered an optimal option following H. pylori eradication therapy. Also, we investigated the healing effect of combination therapy including rabeprazole or teprenone with H. pylori eradication in ESD patients with artificial ulcers [14] . The teprenone group did not have better results than the rabeprazole group in patients with ulcers of more than 1.5 cm diameter. Thus, limitations may exist to the use of combination therapy (especially H. pylori eradication plus cytoprotective agents) in patients with large artificial ulcers after ESD.
There was only one report on the effect of Helicobacter pylori eradication monotherapy on gastric ulcer healing after endoscopic mucosal resection. Cheon et al. found that the ulcer reduction ratio was significantly higher in the H. pylori eradication group compared with the PPI group at 4 weeks after endoscopic mucosal resection [8] . Moreover, no serious adverse events such as bleeding were observed. The end point of their study was the ulcer reduction, not healing, ratio at 4 weeks after EMR, not ESD. In the present study, the reduction ratio of the artificial ulcer area at day 7 in the eradication plus rebamipide group was higher than that in the PPI group. Since eradication therapy is treated with double-dose PPI, the ulcer reduction ratio in the initial phase (from 1 to 4 weeks) may be higher than that in the PPI group. Concerning the term of administration, Niimi et al. [15] reported that 2-week administration of PPI for post-ESD gastric ulcers may be sufficient to aid healing without increasing adverse effects. This report may suggest obtaining sufficient efficacy by adding 2-week administration of PPI in combination therapy including eradication therapy and a cytoprotective agent. Eradication can be performed at many different times (e.g., before or just after ESD, after ulcer healing), but the pros and cons of treatment timing have not been investigated in a formal study. Our study is significant in that it provides some evidence to consider when debating the pros and cons of eradication therapy just after ESD. Given that a double dose of PPI during eradication therapy may promote ulcer healing, using rebamipide after eradication, unlike PPIs, allows assessment of eradication 8 weeks after ESD (when ulcer healing is checked). This reduces costs and patient burden. Unless eradication just after ESD is shown to have drawbacks, this treatment method may be a viable option. A limitation of this study was not evaluating the comparison of H. pylori eradication monotherapy and PPI therapy. We previously demonstrated the efficacy of H. pylori eradication therapy compared with PPI therapy for gastric ulcers. H. pylori eradication therapy was weaker than PPI monotherapy. Furthermore, in the H. pylori eradication therapy group, adverse events such as bleeding have been observed in some patients [9] . Because of ethical considerations, we conducted the present study to investigate the effect of rebamipide following H. pylori eradication Comparisons between groups A and B were performed by using Fisher's exact test Comparisons between group A and B were carried out using Fisher's exact test therapy compared with PPI monotherapy. In this study, the sample size was small. However, we confirmed H. pylori eradication therapy plus 7 weeks rebamipide monotherapy was not superior to PPI monotherapy. In the next step, a comparative study of 8-week PPI therapy and 7-week PPI therapy following H. pylori eradication therapy is needed.
In conclusion, H. pylori eradication therapy plus 7-week rebamipide monotherapy was not superior to PPI monotherapy, but eradication plus rebamipide therapy for smaller sized artificial ulcers was an optimal therapeutic option for healing. Serious adverse events were not observed in eradication plus rebamipide therapy compared with PPI therapy.
